Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

9.600 +0.040 (+0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 88,833
Open 9.580
Bid (Size) 8.650 (1)
Ask (Size) 9.660 (2)
Prev. Close 9.560
Today's Range 9.300 - 9.940
52wk Range 9.260 - 23.64
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Becton, Dickinson and Company, Applied Digital, POSCO And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga

Performance

YTD
-31.53%
-31.53%
1 Month
-13.75%
-13.75%
3 Month
-19.93%
-19.93%
6 Month
-17.10%
-17.10%
1 Year
-23.26%
-23.26%

More News

Read More
Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential
Via Benzinga
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
Janux Therapeutics: Q1 Earnings Insights
Via Benzinga
Janux Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Janux Therapeutics Shares Rose 33.1% This Week
Via The Motley Fool
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
Via Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
From Janux Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks for Bold Contrarians to Consider
Via InvestorPlace
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks to Buy for Contrarian Investors
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.